Press Release

RhoVac recruits Steffen Wad Jørgensen as Chief Development Officer

Dec 04, 2019

RhoVac AB ("RhoVac") announces today, December 4th 2019, that Steffen Wad Jørgensen is appointed Chief Development Officer as of January 1, 2020. In light of Anders Ljungqvist's coming retirement in 2020, Steffen Wad Jørgensen will gradually assume the overall responsibility for the further development of the RV001 project.

RhoVac announces that Steffen Wad Jørgensen is appointed Chief Development Officer as of January 1, 2020. He will gradually assume the overall responsibility for the development project RV001 from Anders Ljungqvist, who will retire later in 2020. However, also after retirement form his operational assignment, Anders Ljungqvist aims to continue on RhoVac's board and as an advisor to the company.

Steffen Wad Jørgensen comes to RhoVac with a long and solid background as a drug developer. Steffen holds a pharmacy degree, and he also holds a PhD in Immunology and Clinical Chemistry. His broad experience includes both formulation development and analysis as well as project coordination of both early and late stage development phases. Most pertinent for the assignment at RhoVac is that Steffen, over the course of his long tenure with Lundbeck, has been promoted to increasingly senior positions within project management in research & development, and that he has also gained many years of experience in both early and late development phases, which is essential for the development of the RV001 project.

Comment from Anders Ljungqvist, COO: “I am glad that we have found the right person to take over operationally when I intend to retire during the course of 2020. I feel confident that Steffen will lead the RV001 project all the way to the finishing line in the best possible way. As one of RhoVac's largest shareholders, I intend to continue my work on the Board with full force. "

Comment from Anders Månsson, CEO: “As Anders Ljungqvist expressed his wish to retire from his operational assignment during the course of 2020, I am very pleased that we have found a good replacement in Steffen. The fact that Steffen starts as early as January means that he and Anders Ljungqvist will have all the time needed to hand over development responsibility in the best possible way ensuring continued project progress and giving Steffen a flying start. The fact that Steffen also he also has solid experience in supporting business development from his time at Lundbeck, I see as a pivotal advantage." 

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has now passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is immediately launching a major Phase IIb clinical trial that will include at least 175 prostate cancer patients. The study, which is expected to be completed in 2021, is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com